A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer

BACKGROUND: HER2-positive (+) breast cancers, defined by HER2 overexpression and/or amplification, are often addicted to HER2 to maintain their malignant phenotype. Yet, some HER2+ tumors do not benefit from anti-HER2 therapy. We hypothesize that HER2 amplification levels and PI3K pathway activation...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Oncol
Main Authors: Veeraraghavan, J, Angelis, C De, Mao, R, Wang, T, Herrera, S, Pavlick, A C, Contreras, A, Nuciforo, P, Mayer, I A, Forero, A, Nanda, R, Goetz, M P, Chang, J C, Wolff, A C, Krop, I E, Fuqua, S A W, Prat, A, Hilsenbeck, S G, Weigelt, B, Reis-Filho, J S, Gutierrez, C, Osborne, C K, Rimawi, M F, Schiff, R
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6594453/
https://ncbi.nlm.nih.gov/pubmed/30903140
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdz076
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados